Xeris Biopharma Holdings Inc (XERS)
2.92
-0.13
(-4.26%)
USD |
NASDAQ |
Nov 15, 16:00
2.93
+0.01
(+0.34%)
After-Hours: 20:00
Xeris Biopharma Holdings Research and Development Expense (TTM): 25.85M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 25.85M |
| June 30, 2024 | 25.00M |
| March 31, 2024 | 25.32M |
| December 31, 2023 | 22.34M |
| September 30, 2023 | 20.91M |
| June 30, 2023 | 21.92M |
| March 31, 2023 | 19.55M |
| December 31, 2022 | 20.97M |
| September 30, 2022 | 26.09M |
| June 30, 2022 | 25.71M |
| March 31, 2022 | 27.38M |
| December 31, 2021 | 25.16M |
| September 30, 2021 | 20.19M |
| June 30, 2021 | 18.40M |
| Date | Value |
|---|---|
| March 31, 2021 | 18.31M |
| December 31, 2020 | 20.92M |
| September 30, 2020 | 28.23M |
| June 30, 2020 | 39.87M |
| March 31, 2020 | 53.92M |
| December 31, 2019 | 60.44M |
| September 30, 2019 | 60.41M |
| June 30, 2019 | 55.76M |
| March 31, 2019 | 45.11M |
| December 31, 2018 | 40.65M |
| September 30, 2018 | 34.84M |
| June 30, 2018 | 29.69M |
| March 31, 2018 | 25.22M |
| December 31, 2017 | 20.17M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
18.31M
Minimum
Mar 2021
60.44M
Maximum
Dec 2019
27.32M
Average
25.08M
Median
Research and Development Expense (TTM) Benchmarks
| Zevra Therapeutics Inc | 46.33M |
| NovaBay Pharmaceuticals Inc | 0.064M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.61M |